A Phase 2 Randomized Trial of Docetaxel Alone or in Combination with a Therapeutic Cancer Vaccine (PANVAC) in Patients with Metastatic Breast Cancer

摘要

IMPORTANCEPrevious phase 1 and 2 trials of PANVAC, a poxviral-based cancer vaccine, suggested clinical efficacy in some patients with breast, ovarian, and colorectal cancer, and evidence of immunologic activity. Preclinical data showed docetaxel can modify tumor phenotype, making tumor cells more amenable to T-cell-mediated killing.